Illumina, Inc. $ILMN Stock Sold by Insight Wealth Strategies LLC

Insight Wealth Strategies LLC trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 25.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,488 shares of the life sciences company’s stock after selling 8,479 shares during the period. Insight Wealth Strategies LLC’s holdings in Illumina were worth $6,702,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ILMN. Fiduciary Financial Advisors purchased a new position in shares of Illumina during the second quarter worth $26,000. MCF Advisors LLC boosted its holdings in Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 100 shares during the last quarter. Keating Financial Advisory Services Inc. acquired a new stake in Illumina during the 2nd quarter worth about $32,000. Rakuten Securities Inc. purchased a new position in shares of Illumina during the 2nd quarter valued at about $33,000. Finally, Elevation Wealth Partners LLC raised its stake in shares of Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after buying an additional 84 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of Illumina stock traded up $7.76 on Friday, hitting $272.33. The company’s stock had a trading volume of 729,119 shares, compared to its average volume of 2,169,474. The company has a market capitalization of $41.12 billion, a price-to-earnings ratio of 50.77, a price-to-earnings-growth ratio of 3.79 and a beta of 1.41. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $309.35. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm has a fifty day moving average price of $225.72 and a 200-day moving average price of $180.21.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.Illumina’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent research reports. Sanford C. Bernstein restated a “market perform” rating and issued a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Argus boosted their price target on Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. Barclays upped their price objective on Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a research report on Wednesday. Leerink Partners raised their price objective on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $222.19.

Insider Activity

In related news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders sold 2,061,850 shares of company stock worth $436,479,102. Company insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.